Search Results

FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46.

Fortis Life Sciences today announced it is the exclusive channel partner for AccuGenomics in the Unites States, with co-exclusive rights in Europe.

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has lifted the clinical hold on January 19th for the FORTIS Ph1/2 clinical trial evaluating the safety, tolerability and efficacy of investigational AT845 in adults with late-onset Pompe disease.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD).

Astellas Pharma Inc. announced that the US Food and Drug Administration has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event of peripheral sensory neuropathy in one of the trial participants.

Astellas Pharma Inc. today announced positive interim safety data from FORTIS, the Phase I/II clinical trial evaluating AT845.

Allegria Therapeutics, a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced a Seed Financing of USD 3.5 Million by founding investor Forty51 Ventures.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead (“Purchaser”), to acquire Forty Seven, Inc. (Nasdaq: FTSV) for $95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate. On March 2, 2020, Gilead and Forty Seven announced that Forty S

Alivexis, Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, announced that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential.